Every material Form 8-K Traws Pharma, Inc. has filed with the SEC since July 31, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Traws Pharma entered a Common Stock Purchase Agreement with Roth Principal Investments, allowing the company to sell up to $50,000,000 of newly issued common stock over time at its own discretion. The company is under no obligation to sell any shares, and sales can begin only after a registration statement covering the resale of those shares is declared effective by the SEC.
Total commitment of up to $50,000,000 in newly issued common stock, at the company's option
Purchase price set at 94.0% of volume weighted average price, a fixed 6.0% discount, for market open, intraday, pre-market and post-market purchases
Sales require the closing price to be at least $0.10 (Threshold Price) and an effective registration statement; the period runs 36 months from the Commencement Date
Agreement dated October 23, 2026, with a related Registration Rights Agreement
Traws Pharma reported its quarter ended June 30, 2026, with no revenue, compared with $2.7 million a year earlier, and a net loss of $3.0 million, or $0.16 per share, versus a $0.9 million loss, or $0.11 per share, in the same period of 2025. The company said its cash and equivalents, plus expected at-the-market equity proceeds, should fund operations into the first quarter of 2027, and that it may need additional financing after that.
Q2 2026 revenue was zero, down from $2.7 million in Q2 2025, which included a non-recurring deferred revenue recognition tied to a licensing termination.
Q2 2026 net loss was $3.0 million ($0.16 per share); six-month net loss was $10.2 million, compared with $20.6 million net income in the first half of 2025, which included a $26.7 million non-cash warrant gain.
Cash and cash equivalents were $5.0 million at June 30, 2026, up from $3.8 million at December 31, 2025, mainly from the April 2026 private placement and ATM sales.
Shareholders approved the Series B and Series C financing tranches on July 8, 2026; the company says access remains subject to milestones and investor participation, and the FDA clinical hold on tivoxavir marboxil is still pending resolutio
Traws Pharma received a Nasdaq notice on July 29, 2026 that its common stock has traded below $1.00 per share for at least 30 consecutive business days, so it is not currently meeting the minimum bid price requirement. The notice has no immediate effect on the listing, but the company has until January 25, 2027 to regain compliance, and it could face delisting if it does not.
Nasdaq notice received July 29, 2026 under Listing Rule 5550(a)(2)
Closing bid price was below $1.00 for at least 30 consecutive business days
Compliance period runs until January 25, 2027; regaining compliance requires at least 10 consecutive business days at or above $1.00
A second 180-day grace period may be available if the company meets listing standards and gives notice of intent to cure
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Traws Pharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →